Similarly, centrally applied analog of glucagon-like peptide 1 (GLP-1—liraglutide) affected proUGN expression and was associated with increased basal BAT activity but reduced BAT activation after a meal in patients with T2D receiving GLP-1 therapy. Here, GCG is linked to type 2 diabetes mellitus.